These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 17212661)
21. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Cornolti G; Ungari M; Morassi ML; Facchetti F; Rossi E; Lombardi D; Nicolai P Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328 [TBL] [Abstract][Full Text] [Related]
22. Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines. Jones J; Lagasse LD; Karlan BY Gynecol Oncol; 1994 Dec; 55(3 Pt 1):421-6. PubMed ID: 7835782 [TBL] [Abstract][Full Text] [Related]
23. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer. Naeem M; Nasir A; Aman Z; Ahmad T; Samad A J Ayub Med Coll Abbottabad; 2008; 20(3):23-6. PubMed ID: 19610508 [TBL] [Abstract][Full Text] [Related]
24. Effect of pesticide exposure on HER-2/neu overexpression seen in patients with extensive stage small cell lung carcinoma. Potti A; Ganti AK; Sholes K; Langness E; Koka V; Horvarth L; Koch M Clin Cancer Res; 2003 Oct; 9(13):4872-6. PubMed ID: 14581360 [TBL] [Abstract][Full Text] [Related]
25. Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. Mano MS; Awada A; Di Leo A; Durbecq V; Paesmans M; Cardoso F; Larsimont D; Piccart M Gynecol Oncol; 2004 Mar; 92(3):887-95. PubMed ID: 14984957 [TBL] [Abstract][Full Text] [Related]
26. Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme. Koka V; Potti A; Forseen SE; Pervez H; Fraiman GN; Koch M; Levitt R Am J Clin Oncol; 2003 Aug; 26(4):332-5. PubMed ID: 12902879 [TBL] [Abstract][Full Text] [Related]
27. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma. Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D J BUON; 2007; 12(1):99-104. PubMed ID: 17436409 [TBL] [Abstract][Full Text] [Related]
28. Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients. Hoopmann M; Sachse K; Valter MM; Becker M; Neumann R; Ortmann M; Göhring UJ; Thomas A; Mallmann P; Schöndorf T Eur J Cancer Care (Engl); 2010 Nov; 19(6):809-15. PubMed ID: 20105224 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology. Sanchez KM; Sweeney CJ; Mass R; Koch MO; Eckert GJ; Geary WA; Baldridge LA; Zhang S; Eble JN; Cheng L Cancer; 2002 Oct; 95(8):1650-5. PubMed ID: 12365012 [TBL] [Abstract][Full Text] [Related]
30. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization. Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576 [TBL] [Abstract][Full Text] [Related]
31. Pathology of borderline HER-2/neu breast carcinoma: a biologically distinct phenotype. Killeen JL; Ortega-Lopez A; Shaha J; Shaha SH; Fu JB Breast Cancer Res Treat; 2006 Jul; 98(1):99-108. PubMed ID: 16538540 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer. Homaei-Shandiz F; Ghavam-Nassiri MR; Sharifi N; Homaei-Shandiz AH; Taghizadeh-Kermani A; Torshizi SA; Ghafarzadegan K Saudi Med J; 2006 Dec; 27(12):1810-4. PubMed ID: 17143354 [TBL] [Abstract][Full Text] [Related]
33. The prognostic value of HER-2/neu oncogene in cervical cancer. Ndubisi B; Sanz S; Lu L; Podczaski E; Benrubi G; Masood S Ann Clin Lab Sci; 1997; 27(6):396-401. PubMed ID: 9433536 [TBL] [Abstract][Full Text] [Related]
34. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer. Ivkovic-Kapicl T; Knezevic-Usaj S; Djilas-Ivanovic D; Panjkovic M In Vivo; 2007; 21(4):673-8. PubMed ID: 17708365 [TBL] [Abstract][Full Text] [Related]
35. Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer. Kohlberger P; Loesch A; Koelbl H; Breitenecker G; Kainz C; Gitsch G Cancer Lett; 1996 Jan; 98(2):151-5. PubMed ID: 8556702 [TBL] [Abstract][Full Text] [Related]
36. Clinical relevance of HER-2/neu expression in germ-cell testicular tumors. Mándoky L; Géczi L; Bodrogi I; Tóth J; Csuka O; Kásler M; Bak M Anticancer Res; 2004; 24(4):2219-24. PubMed ID: 15330164 [TBL] [Abstract][Full Text] [Related]
37. Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors. Forseen SE; Potti A; Koka V; Koch M; Fraiman G; Levitt R Anticancer Res; 2002; 22(3):1599-602. PubMed ID: 12168843 [TBL] [Abstract][Full Text] [Related]
38. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038 [TBL] [Abstract][Full Text] [Related]
39. HER-2/neu and p27Kip1 in progression of Fallopian tube carcinoma: an immunohistochemical and array comparative genomic hybridization study. Nowee ME; Dorsman JC; Piek JM; Kosma VM; Hämäläinen K; Verheijen RH; van Diest PJ Histopathology; 2007 Nov; 51(5):666-73. PubMed ID: 17927588 [TBL] [Abstract][Full Text] [Related]
40. Her-2/neu gene overexpression in breast carcinoma and its association with clinicopathological characteristics of the disease. Ahmad A; Bano U; Gondal M; Khan A J Coll Physicians Surg Pak; 2009 May; 19(5):297-9. PubMed ID: 19409162 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]